Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Thyroid stimulating hormone increases iodine uptake by thyroid cancer cells during BRAF silencing.

The Journal of surgical research - 1 Jun 2013

Kleiman David A, Buitrago Daniel, Crowley Michael J, Beninato Toni, Veach Alexander J, Zanzonico Pat B, Jin Moonsoo, Fahey Thomas J, Zarnegar Rasa

Abstract excerpt

BACKGROUND: The BRAF(V600E) mutation is present in 62% of radioactive iodine-resistant thyroid tumors and is associated with downregulation of the sodium-iodide symporter (NIS) and thyroid stimulating hormone receptor (TSHr). We sought to evaluate the combined effect of BRAF inhibition and TSH supplementation on (131)I uptake of BRAF(V600E)-mutant human thyroid cancer cells. MATERIALS AND METHODS: WRO cells (a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma, Follicular
Share to Gene Silencing

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Iodine

Share to Iodine Radioisotopes

Share to Receptors, Thyrotropin

Share to Symporters

Share to Thyroid Neoplasms

Share to Thyrotropin

Source

Open in PubMed Open full text

Identifiers

PMID: 22998776
DOI: 10.1016/j.jss.2012.08.053
PMCID: PMC3652238

Genes

BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Thyroid stimulating hormone increases iodine uptake by thyroid cancer cells during BRAF silencing.PMID 22998776Read ↗

BRAF Mutations in Papillary Thyroid Carcinomas Inhibit Genes Involved in Iodine MetabolismSemantic proximity Read ↗

Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activationSemantic proximity Read ↗

Different expression of TSH receptor and NIS genes in thyroid cancer: role of epigeneticsSemantic proximity Read ↗

The BRAF V600E mutation is a predictor of the effect of radioiodine therapy in papillary thyroid cancerSemantic proximity Read ↗

Do BRAFV600E mutation and sodium-iodide symporter expression affect the response to radioactive iodine therapy in patients with papillary thyroid carcinoma?Semantic proximity Read ↗

Robust Thyroid Gene Expression and Radioiodine Uptake Induced by Simultaneous Suppression of BRAF V600E and Histone Deacetylase in Thyroid Cancer CellsSemantic proximity Read ↗

Targeting miR‐31 represses tumourigenesis and dedifferentiation of BRAF V600E ‐associated thyroid carcinomaSemantic proximity Read ↗

New mechanisms of radioiodide uptake revealed via a novel high throughput drug screening approach in thyroid cancerSemantic proximity Read ↗

Radioiodine Therapy in Differentiated Thyroid Cancer: The First Targeted Therapy in OncologySemantic proximity Read ↗

Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer.Semantic proximity Read ↗

MAPK pathway inhibitors enhance radioiodine sensitivity in anaplastic thyroid carcinoma through promoting NIS expression and ARF4-mediated NIS membrane transportSemantic proximity Read ↗

The role of BRAF V600E mutation in post-surgical 131I therapy in papillary thyroid carcinoma: a study based on SPECT-CT uptake analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.